Get the Stockscreener App
0.6108
1.80%
0.0108
After Hours:
.62
0.0092
+1.51%
Longeveron Inc stock is traded at $0.6108, with a volume of 167.90K.
It is up +1.80% in the last 24 hours and down -14.63% over the past month.
Longeveron Inc is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. Its investigational product candidate is laromestrocel. Laromestrocel is a proprietary, scalable, allogeneic cellular therapy that has multiple potential modes of action that include pro-vascular, pro-regenerative, and anti-inflammatory mechanisms that collectively appear to promote tissue repair and healing. It is in clinical development of a single investigational product candidate, laromestrocel, for four potential indications: HLHS, Alzheimer's disease (AD), Pediatric Dilated Cardiomyopathy (pediatric DCM), and Aging-related Frailty. It operates in a single operating segment focused on developing regenerative medicines to address unmet medical needs.
See More
Previous Close:
$0.60
Open:
$0.5751
24h Volume:
167.90K
Relative Volume:
0.56
Market Cap:
$19.30M
Revenue:
$1.22M
Net Income/Loss:
$-22.43M
P/E Ratio:
-0.5282
EPS:
-1.1564
Net Cash Flow:
$-18.78M
1W Performance:
+1.43%
1M Performance:
-14.63%
6M Performance:
+5.40%
1Y Performance:
-63.43%
1-Day Range:
$0.5751
$0.62
1-Week Range:
$0.5751
$0.6575
52-Week Range:
$0.475
$1.75
Longeveron Inc Stock (LGVN) Company Profile
Name
Longeveron Inc
Sector
Industry
Phone
305-302-7158
Address
1951 NW 7TH AVENUE, MIAMI
Compare LGVN vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LGVN
Longeveron Inc
|
0.6108 | 18.96M | 1.22M | -22.43M | -18.78M | -1.1564 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Longeveron Inc Stock (LGVN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-06-24 | Initiated | ROTH MKM | Buy |
Longeveron Inc Stock (LGVN) Latest News
Longeveron Inc (LGVN) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Longeveron Inc (LGVN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Longeveron Inc (LGVN) Cash Flow - TradingKey
Longeveron Inc (LGVN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
LGVN|Longeveron Inc|Price:0.600|Chg%:-0.007 - TradingKey
TradingKey - TradingKey
Longeveron Inc (LGVN) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Deborah D. Ascheim, M.D. Elected to Longeveron Board of Directors - BioSpace
Longeveron Inc. Elects Deborah D. Ascheim, M.D., to Board of Directors - Quiver Quantitative
LGVN Stock Slips After Hours As FDA Flags Concerns On Rare Heart Defect Trial Design - Stocktwits
Longeveron : Initial Statement of Beneficial Ownership (Form 3) - marketscreener.com
Longeveron Enhances CEO Compensation and Retention Protections - TipRanks
Can Upcoming HLHS Trial Data Drive A Valuation Re-Rating For Longeveron? - RTTNews
Longeveron Inc. Signs Revised CEO Employment Agreement – Key Details from July 2026 Form 8-K Filing - Minichart
Longeveron Inc. (LGVN) director files Form 3 showing no share holdings - Stock Titan
Longeveron (NASDAQ: LGVN) updates CEO severance and equity vesting - Stock Titan
Longeveron Inc. (LGVN) director Leah Cann reports no stock ownership - Stock Titan
Longeveron Presents AAIC Data Showing Laromestrocel Stabilizes Brain Inflammation in Alzheimer’s Disease - Quiver Quantitative
Stem cell therapy laromestrocel links brain scan changes to better cognition in Alzheimer’s trial - Stock Titan
Longeveron (LGVN) Sees Modest Uptick as Stock Nears $0.69 ResistanceChandelier Stop - dars.gov.et
Longeveron Inc. Issues Special Equity Awards to Executive Chairman – SEC 8-K Filing Highlights Company Growth 7 - Minichart
Form 4 Longeveron LLC For: 8 July By Investing.com - Investing.com Nigeria
Longeveron (LGVN) CSO Hare granted 600k RSUs and 400k options - Stock Titan
Longeveron grants special equity awards to Executive Chairman - TipRanks
Longeveron (LGVN) awards 600,000 RSUs and 400,000 options to Executive Chairman - Stock Titan
Longeveron strengthens financial leadership with new CFO appointment - The Globe and Mail
symbol__ Stock Quote Price and Forecast - CNN
Longeveron names Marie Washburn as CFO - MSN
Form 4 Longeveron LLC For: 6 July By Investing.com - Investing.com Nigeria
Longeveron (NASDAQ: LGVN) CTO has 15,808 shares withheld for taxes - Stock Titan
Longeveron (LGVN) CFO has shares withheld to cover RSU tax obligations - Stock Titan
Longeveron (LGVN) CMO reports 22,505-share tax withholding after RSU vesting - Stock Titan
Longeveron Appoints Marie Washburn as Chief Financial Officer - citybiz
New Longeveron (NASDAQ: LGVN) CFO and reverse stock split approval - Stock Titan
Longeveron® Appoints Marie Washburn as Chief Financial Officer - GlobeNewswire
Longeveron Inc. (LGVN) Drops Over 7% as Biotech Sentiment WeighsEarly Entry Signals - dars.gov.et
Longeveron appoints Marie Washburn as CFO amid upcoming Phase 2b stem cell trial results. - Pluang
Longeveron (LGVN) Slips as Bearish Momentum Pressures Support at $0.66Mutual Fund Flow - dars.gov.et
LGVN Q1 2026 Earnings: EPS Misses Estimates as Clinical-Stage Biotech Reports Wider-Than-Expected Loss - DonanımHaber
Price to sales forward of Longeveron Inc. – NASDAQ:LGVN - TradingView
Enterprise value to revenue forward of Longeveron Inc. – NASDAQ:LGVN - TradingView
Enterprise value to EBIT forward of Longeveron Inc. – NASDAQ:LGVN - TradingView
Enterprise value to EBITDA forward of Longeveron Inc. – NASDAQ:LGVN - TradingView
Price to book forward of Longeveron Inc. – NASDAQ:LGVN - TradingView
Price to earnings forward of Longeveron Inc. – NASDAQ:LGVN - TradingView
Longeveron® Announces Second Quarter 2025 Financial Results and Provides Business Update - The National Law Review
Longeveron® Announces First Quarter 2025 Financial Results and Provides Business Update - The National Law Review
LGVN Shares Rise After Investigational Therapy Shows Improvement In Age-Related Frailty Study - Stocktwits
Longeveron Inc. Class A Actuals & Estimates (NASDAQ:LGVN) - TradingView
LGVN Forecast — Price Target — Prediction for 2027 - TradingView
LGVN News | LONGEVERON INC-A (NASDAQ:LGVN) - ChartMill
Longeveron Inc Stock (LGVN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.97%
0.83%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):